Weak Start Masks the Real Story: Order Book Is Credible, Working Capital Is Not
H1 profit was withheld from disclosure, revenue limped at ₹74 Cr, yet management guided H2 at ₹310–₹325 Cr with an order book of ₹1,200–₹1,500 Cr. The stock is down 33% from its all-time high. This is a first post-IPO earnings call, and the tension is real: order visibility is there, but working capital intensity and execution risk are priced in by the market.
₹74 Cr
near break-even, PAT withheld
₹310–₹325 Cr
4.2x H1; execution bet
~₹384–₹399 Cr
implies ₹270–₹280 Cr H2 actual
₹1,200–₹1,500 Cr
2–3 year visibility
16.2%
+210 bp YoY
17–18%
sustainable, management claims
250–300 days
improving Apr 2027
63%
6,300 orders won
Acme India is a first post-IPO earnings surprise: not because the numbers pop, but because they don't. H1 revenue of ₹74 Cr was described as a loss, profitability withheld from disclosure—a transparency red flag for a newly listed company. Yet management guided H2 at ₹310–₹325 Cr, a 4.2x jump, anchored to an order book of ₹1,200–₹1,500 Cr. The street has repriced the stock down 33% from its all-time high, signalling skepticism on execution. The debate is real: Can a first-time management team with a 250–300 day receivables cycle and 100% customer concentration (Indian Railways) execute a 4x revenue ramp in H2 without working capital collapse?
The gap between H1 and H2: A quarter of lumpy seasonality
Acme's revenue profile is structurally seasonal—railway tenders are awarded in Nov–Jan, delivery billing concentrated in Feb–Mar. H1 FY27 reflects this: tender awards late in the quarter compressed cash collection into the final weeks. ₹74 Cr H1 revenue was always going to be weak; the issue is profitability stayed flat. Management disclosed EBITDA but withheld PAT, implying H1 net profit was near-zero or negative—a material earnings transparency gap for a newly listed company. EBITDA of 16.2% (up 210 bp YoY) suggests cost controls are working, but fixed cost loading at low revenue volume explains why margin expansion didn't translate to profit growth.
H2 is structurally the strong half for railways: capex budget year-end push (Feb–Mar) drives delivery billing. Management expects ₹310–₹325 Cr H2 revenue, implying ₹270–₹280 Cr actual cash billings from an order book of ₹700+ Cr (₹630–₹750 Cr fill from new orders)—90% of that executed in FY27. Payment terms are 50–60% on supply, 40% on completion, locked by contract. The order book is government-backed and tendered; execution risk is low once awarded. The real risk is working capital cycle: if billings bunch in Feb–Mar, cash sits 250–300 days awaiting payment, straining liquidity even as the order book swells.
Claims vs. what holds up
H2 revenue ₹310–₹325 Cr will drive profitability
H1 ₹74 Cr on loss/near-zero PAT; H2 guidance 4.2x higher but payment cycle same (250–300 days). Profit recovery contingent on operating leverage, not volume alone.
Slightly overstated
Order book ₹1,200–₹1,500 Cr by H2 FY27
₹700+ Cr published & tendered; ₹500–₹800 Cr expected from pending tenders & new coach variants (Vande Bharat). LOI & payment terms confirmed by railway.
Supported
EBITDA margin 17–18% is sustainable
H1 achieved 16.2% at 33% factory utilization. H2 at higher volume, operating leverage will lift margin. No product mix improvement required—fixed cost absorption sufficient.
Supported
Market leadership: 63% share in toilet tenders
6,300 orders won out of ~10,000 tendered for toilet modernization segment. Highest moat due to 4–5 year prototype credibility & global partner tech tie-ups.
Supported
PAT margin 11–11.5% FY27 onwards
Interest cost declining (IPO debt paydown: ₹5.5–₹6 Cr full-year FY27). Fixed cost leverage as volume grows. Achievable but contingent on payment cycle normalization (Apr 2027 target).
Supported
Railway order book subject to no deferral risk
Railways have revenue model (passenger earnings pay for capex); orders are budget-committed & tendered. Politcal will ensures spend. No alternate suppliers for coach furnishing.
Supported
What changed on this call
Three material upgrades emerged: (1) Wagon & passenger coach maintenance business newly entered. ACME recently won a ₹32 Cr order in wagon maintenance; partnered with Korean and Russian companies (15–20 year maintenance expertise) for passenger coach segment. This is a new ₹250–₹300 Cr market, adding 10–12 year visibility. (2) Payment cycle normalization expected Apr 2027. Currently lumpy (Feb–Mar concentrated), 250–300 day tail. From Apr 2027, monthly billing replaces lumpiness, reducing working capital drag significantly. (3) Order book upgraded to ₹1,200–₹1,500 Cr by H2. Prior disclosed ₹700+ Cr visible; management now expects ₹500–₹800 Cr incremental from pending tenders (new coach variants, Vande Bharat class expansion).
Working capital: the hidden tension
Risks, ranked by severity for a holder
Working capital cycle collapse if payment regularization slips
High250–300 day receivables + ₹310–₹325 Cr H2 billings = ₹100–₹110 Cr receivables drag into FY28. If Apr 2027 monthly billing doesn't materialize, liquidity crunch will force either credit-line drawdown (eroding profitability) or order slowdown (capping revenue). First post-IPO profitability miss on working capital, not operations, kills credibility.
Single-customer concentration: 100% customer is Indian Railways
HighOrder book is credible but entirely dependent on railway budget cycle, tender pace, and government spending priorities. A macro slowdown or railways budget cut would cascade through ACME's entire order book. Diversification non-existent. FII minimal (1.46%) partly reflects this concentration risk.
H1 PAT not disclosed—earnings quality opacity
MediumRevenue ₹74 Cr, described as 'loss', but exact PAT withheld. For a newly listed company, this is a transparency gap. Investors can't verify profitability trajectory or margin math. If H2 also disappoints on profit (despite EBITDA guidance), credibility craters.
Market share erosion: 63% unsustainable vs. new entrants
MediumACME leads in toilet modernization with 63% tender wins (6,300 orders). But new suppliers (RVNL, BEML, TiTagarh) are entering. L1 bidding system commoditizes margins if competition intensifies. 63% share is 4–5 year durable due to prototype lead; not 10+ year moat.
H2 guidance 4.2x H1: execution slippage risk
MediumIf tender awards or delivery timelines slip, H2 billings could fall short of ₹310–₹325 Cr. This would cascade: missed H2 guidance → working capital assumptions break → FY28 order additions delayed. Market has priced in execution risk; stock down 33% from ATH.
Payment cycle normalization by Apr 2027 is an assumption
LowManagement expects monthly billing from Apr 2027, reducing 250–300 day tail. But railway billing timelines are not fully in ACME's control. If payment lags persist, working capital stress extends into FY28, constraining margin upside.
How the street is positioned—and what the market tells us
Price action: ACME closed at ₹163 on 2026-11-20, down 32.6% from its all-time high of ₹242 and up 20.7% from its 52-week low of ₹135. RSI sits at 37.5 (neutral, neither overbought nor oversold). Volume is increasing, suggesting institutions are actively sizing the stock. The 33% drawdown from ATH is the market's honest read: order book is credible, but working capital intensity and execution risk merit a valuation discount.
Ownership tells the story: FII holdings are minimal at 1.46%—suggesting foreign institutional investors are steering clear of a 100%-railway-dependent, first-time-earnings-call, working-capital-laden story. DII (domestic institutions) hold 10.70%, implying retail and domestic MFs are the primary buyers. Promoters retain 64.46%, a substantial stake, but the dilution post-IPO and weak H1 profitability have dampened institutional appetite. The low FII footprint is a signal: the market doesn't yet trust the cash conversion story.
What this means: The stock has repriced the upside into execution. Order book visibility is priced in at ₹163 (the high of ₹242 assumed flawless H2 delivery). The downside risk (working capital collapse, tender deferrals, margin disappointment) is not fully priced in—there is room to 2–3x down from here if H2 disappoints. Conversely, if ACME executes H2 guidance AND payment regularization materializes by Apr 2027, the stock is not expensive at ₹163 for a 2–3 year visibility story.
The debate
What to watch next quarter
1 · H2 FY27 billing realization: Does ₹310–₹325 Cr guidance hold?
Watch Q3 FY27 (Oct–Dec 2026) for tender award pipeline and early H2 billings. If tender awards accelerate and Q3 billings hit ₹130–₹150 Cr (setting up ₹160–₹180 Cr for Q4), confidence in H2 guidance rises. If tenders stall or Q3 billing disappoints (below ₹100 Cr), H2 target is at risk. This is the linchpin.
2 · PAT disclosure and working capital bridge: Is profitability real?
Full-year guidance expects PAT margin 11–11.5%. Q3 FY27 results must disclose PAT (not withhold like H1). Watch receivables days on the balance sheet—if they fall from 250–300 to 200–220 by Q4, payment regularization is on track. If receivables spike to 300–350+, payment cycle is worsening, signalling working capital stress.
3 · Order book build: Does ₹1,200–₹1,500 Cr materialize by H2?
New tender publications (Vande Bharat class, mid-life rehab) are the leading indicator. Watch for ACME tender wins and LOI announcements. If order book reaches ₹1,100 Cr+ by Q3, confidence in ₹1,200–₹1,500 Cr by H2 rises. If order book stalls at ₹700–₹800 Cr, the 'upgrade' is a mirage, and FY28 revenue target (₹380 Cr) is at risk.
ACME India is a step-change story on order book and margin visibility, but a first-time earnings call with weak H1 profitability and execution uncertainty. The order book of ₹1,200–₹1,500 Cr is tangible and government-backed; the question is whether management can convert ₹310–₹325 Cr H2 billings into profit amid a 250–300 day receivables cycle. The market's 33% repricing from ATH reflects this tension fairly: upside is real if H2 execution and payment regularization hold, downside is severe if either slips.
The number to track from here is working capital days (target: 200–220 by Q4 FY27) and Q3 FY27 billing realization. If those two anchor, the bull case gains ground. If they slip, working capital becomes the story, and the stock could re-rate to ₹110–₹120. Hold at ₹163 pending Q3 FY27 earnings; a credible H2 start (Q3 billings ₹130+ Cr) would justify Buy on visibility, while a miss would warrant reassessment.
Informational and educational content only. Not investment advice.